NO145381C - Analogifremgangsmaate for fremstilling av fysiologisk aktive prostaglandin-derivater. - Google Patents

Analogifremgangsmaate for fremstilling av fysiologisk aktive prostaglandin-derivater.

Info

Publication number
NO145381C
NO145381C NO754174A NO754174A NO145381C NO 145381 C NO145381 C NO 145381C NO 754174 A NO754174 A NO 754174A NO 754174 A NO754174 A NO 754174A NO 145381 C NO145381 C NO 145381C
Authority
NO
Norway
Prior art keywords
preparation
physiologically active
prostaglandin derivatives
analogue procedure
active prostaglandin
Prior art date
Application number
NO754174A
Other languages
English (en)
Norwegian (no)
Other versions
NO145381B (no
NO754174L (cs
Inventor
Michael Ross Johnson
Thomas Ken Schaaf
James Frederick Eggler
Jasjit Singh Bindra
Hans-Jurgen Ernst Hess
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO754174L publication Critical patent/NO754174L/no
Publication of NO145381B publication Critical patent/NO145381B/no
Publication of NO145381C publication Critical patent/NO145381C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/06—Saturated compounds having a carboxyl group bound to a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1896—Compounds having one or more Si-O-acyl linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4056—Esters of arylalkanephosphonic acids
    • C07F9/4059—Compounds containing the structure (RY)2P(=X)-(CH2)n-C(=O)-(CH2)m-Ar, (X, Y = O, S, Se; n>=1, m>=0)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO754174A 1974-12-11 1975-12-09 Analogifremgangsmaate for fremstilling av fysiologisk aktive prostaglandin-derivater. NO145381C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/531,675 US3932389A (en) 1974-12-11 1974-12-11 2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorprostaglandins

Publications (3)

Publication Number Publication Date
NO754174L NO754174L (cs) 1976-06-14
NO145381B NO145381B (no) 1981-11-30
NO145381C true NO145381C (no) 1982-03-10

Family

ID=24118587

Family Applications (1)

Application Number Title Priority Date Filing Date
NO754174A NO145381C (no) 1974-12-11 1975-12-09 Analogifremgangsmaate for fremstilling av fysiologisk aktive prostaglandin-derivater.

Country Status (24)

Country Link
US (1) US3932389A (cs)
JP (2) JPS5186465A (cs)
AR (1) AR222623A1 (cs)
BE (1) BE836563A (cs)
CA (1) CA1059122A (cs)
CH (2) CH614434A5 (cs)
CS (3) CS191960B2 (cs)
DD (2) DD129644A5 (cs)
DK (1) DK560075A (cs)
ES (1) ES443422A1 (cs)
FI (1) FI62289C (cs)
FR (1) FR2293927A1 (cs)
GB (2) GB1515414A (cs)
GR (1) GR58521B (cs)
HU (1) HU175278B (cs)
IE (1) IE42937B1 (cs)
IL (1) IL48637A (cs)
LU (1) LU73996A1 (cs)
NL (1) NL163509C (cs)
NO (1) NO145381C (cs)
NZ (1) NZ179503A (cs)
SE (2) SE415759B (cs)
YU (1) YU313775A (cs)
ZA (1) ZA757754B (cs)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4102894A (en) * 1975-11-19 1978-07-25 Pfizer Inc. 15-Substituted-ω-pentanorprostaglandins
US4035360A (en) * 1974-12-11 1977-07-12 Pfizer Inc. Magnesium salts of 2-descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-omega-pentanoprostaglandins
US3984400A (en) * 1975-10-21 1976-10-05 Pfizer Inc. 11-Desoxy-16-aryl-ω-tetranorprostaglandins
JPS5295670A (en) * 1976-02-04 1977-08-11 Pfizer 22decarboxyy225 tetrazoll55yl**11deoxyy omegaapentanolprostaglandine
US4342868A (en) * 1977-06-13 1982-08-03 Pfizer Inc. 2-Descarboxy-2-(tetrazol-5-yl)-16,16-dimethyl-17-(2-furyl)-ω-trisnorprostaglandin E2
US4404372A (en) * 1977-06-13 1983-09-13 Pfizer Inc. 15-Substituted-ω-pentanorprostaglandin derivatives
US4097601A (en) * 1977-08-26 1978-06-27 Pfizer Inc. Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins
JPS54119464A (en) * 1979-02-02 1979-09-17 Pfizer Intermediate for manufacturing 22decarboxyy 22*tetrasoll55yl**111deoxyyomegaapentanol prostaglandin
JPS54119465A (en) * 1979-02-02 1979-09-17 Pfizer Intermediate for manufacturing 22decarboxyy 22*tetrasoll55yl**111deoxyyomegaapentanol prostaglandin
US4336372A (en) * 1979-04-02 1982-06-22 The Upjohn Company 2-Decarboxy-2-tetrazolyl-PG2 compounds
US4336393A (en) * 1979-04-02 1982-06-22 The Upjohn Company 2-Decarboxy-2-tetrazolyl-13,14-dihydro-PG1 compounds
US4336371A (en) * 1979-04-02 1982-06-22 The Upjohn Company 2-Decarboxy-2-tetrazolyl-13,14-dihydro-PG2 compounds
US4336392A (en) * 1979-04-02 1982-06-22 The Upjohn Company 2-Decarboxy-2-tetrazolyl-PG1 compounds
JPS5991116U (ja) * 1982-12-09 1984-06-20 名倉　啓介 バツクル
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US6531485B2 (en) 1997-06-23 2003-03-11 Pfizer Inc. Prostaglandin agonists
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
US20020161026A1 (en) * 2000-11-07 2002-10-31 Paralkar Vishwas M. Combination therapies for the stimulation of bone growth
WO2003018025A1 (en) * 2001-08-23 2003-03-06 Sucampo Ag Method and composition for treatment of ocular hypertension and glaucoma
AU2003209571A1 (en) * 2002-03-18 2003-09-29 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
US20030220377A1 (en) * 2002-05-08 2003-11-27 Richard Chesworth Indole compounds and their use as estrogen agonists/antagonists
US20040002524A1 (en) * 2002-06-24 2004-01-01 Richard Chesworth Benzimidazole compounds and their use as estrogen agonists/antagonists
US20050203086A1 (en) * 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
US9284274B2 (en) 2005-12-07 2016-03-15 Ramot At Tel-Aviv University Ltd. Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
US20090291904A1 (en) * 2005-12-07 2009-11-26 Yoel Kashman Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
US9284252B2 (en) 2009-06-09 2016-03-15 Sepal Pharma Ltd. Use of jasmonate ester derivatives for treating benign hyperproliferative skin disorders
US12589097B2 (en) 2018-02-21 2026-03-31 OrphAl Therapeutics Inc. Apilimod compositions and methods of use
AU2019223014B2 (en) 2018-02-21 2024-10-17 Orphai Therapeutics Inc. Combination therapy with apilimod and glutamatergic agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788209A (fr) * 1971-09-01 1973-02-28 Pfizer Derives tetrazoyliques des prostaglandines naturelles

Also Published As

Publication number Publication date
GB1515414A (en) 1978-06-21
JPS541711B2 (cs) 1979-01-27
YU313775A (en) 1982-06-30
GR58521B (en) 1977-10-29
BE836563A (fr) 1976-06-11
FI62289C (fi) 1982-12-10
NO145381B (no) 1981-11-30
GB1515415A (en) 1978-06-21
IE42937L (en) 1976-06-11
DK560075A (da) 1976-06-12
CS191996B2 (en) 1979-07-31
JPS52116471A (en) 1977-09-29
IE42937B1 (en) 1980-11-19
CH614434A5 (cs) 1979-11-30
NL163509B (nl) 1980-04-15
JPS5186465A (en) 1976-07-29
NO754174L (cs) 1976-06-14
DD129648A5 (de) 1978-02-01
SE7907780L (sv) 1979-09-19
AU8736375A (en) 1977-06-02
CA1059122A (en) 1979-07-24
FR2293927B1 (cs) 1979-02-23
FI62289B (fi) 1982-08-31
IL48637A (en) 1979-12-30
ZA757754B (en) 1976-11-24
HU175278B (hu) 1980-06-28
LU73996A1 (cs) 1976-11-11
SE7513708L (sv) 1976-06-14
NZ179503A (en) 1978-07-10
AR222623A1 (es) 1981-06-15
FR2293927A1 (fr) 1976-07-09
ES443422A1 (es) 1977-04-16
FI753474A7 (cs) 1976-06-12
CS191960B2 (en) 1979-07-31
US3932389A (en) 1976-01-13
NL7514447A (nl) 1976-06-15
CH612188A5 (cs) 1979-07-13
IL48637A0 (en) 1976-02-29
JPS568035B2 (cs) 1981-02-20
CS191995B2 (en) 1979-07-31
NL163509C (nl) 1980-09-15
DD129644A5 (de) 1978-02-01
SE415759B (sv) 1980-10-27

Similar Documents

Publication Publication Date Title
SE415759B (sv) Forfarande for framstellning av vissa 2-dekarboxi-2-(tetrazol-5-yl)-11-desoxi-omega-pentanorprostaglandiner
NO150203C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive 4-hydroksy-2h-1,2-benzotiazin-3-karboksamid-1,1-dioksyder
AR207877A1 (es) Procedimiento para la produccion de trasplantes heterologos de arterias
ES420688A1 (es) Procedimiento para la preparacion de acilanilidas sustitui-das.
NO145657C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive alkenderivater.
ES423870A1 (es) Procedimiento para la obtencion de enonas.
NO138335C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive alkanolaminer
ES419143A1 (es) Procedimiento para la obtencion de derivados del acido prostanoico.
NL7504274A (nl) Werkwijze voor de bereiding van prostaglandine- -preparaten.
IE43462L (en) Substituted tetranorprostaglandins
IE44016L (en) 11-deoxy-16-aryl-17,18,19,20-tetranor-prostaglandins
IT1027065B (it) Procedimento per la preparazione dell aldeide p toluica
IT1032830B (it) Procedimento per la produzione di l cisteina e dei suoi deerivati per via enzimatica
NO144928C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive zantinderivater.
NO145383C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte indoler.
IT1039864B (it) Procedimento per la produzione di l lisina
NO140860C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive triazolo-1,5-benzodiazepiner
NO143499C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive indanderivater
NO141121C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive morfolinderivater
ES490031A0 (es) Procedimiento para la preparacion de nuevos derivados de prostaglandina
NO146280C (no) Bis-tetrahydropyranyleter for anvendelse som mellomprodukt for fremstilling av en fysiologisk aktiv p-bifenylester av en prostaglandinanalog av e- eller f-serien
IT1039086B (it) Procedimento per la produzione dell alcool furfurolico
IT982841B (it) Apparecchio per eseguire la cura delle unghie
IT1044247B (it) Intermedi per la sintesi di derivati b lattamici e procedimento per la loro preparazone
NO144072C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 5-endo-(3-indolkarbonyloksy)-n-(amino-lavere-alkyl)-bicyklo-(82,2,1)-heptan-2,3-diendo-karboksylsyreimider